Featured Article Cover Story Regulatory Updates Launch Product Launch PetMeds Receives New Acquisition Proposal Corporate transaction PetMed Express has received an unsolicited, non-binding proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash. ...
Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Volition is positioning Nu.Q Vet Feline as a potential first scalable, affordable blood test for feline lymphoma, with performance (86% sensitivity at 97% specificity) strong enough to support real-world screening, not just “rule...
Quick Takeaways: Why It Matters? BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level. Ins...
Quick Takeaways: Why It Matters? Automation on the IDS i10 platform lets Volition scale Nu.Q Vet testing volume and speed, making routine cancer screening more practical for large hospital networks. Deeper integration with Fujifilm Vet Systems in Japan also stren...
Quick Takeaways: Why It Matters? MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts par...
Quick Takeaways: Why It Matters? By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing. Bundling mast cell detection at no extra c...
